ALS News Today Home | ALS News Today
WEBAmprion wins $100K to study causes of sporadic ALS. Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease.
New Treatment Strategy Offers Hope for Halting ALS Progression
WEBJan 30, 2024 · A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says.
FDA Approves First ALS Treatment Via Accelerated Approval
WEBApr 25, 2023 · ALS Association Funded Antisense Technology Behind Tofersen. Washington, D.C. (April 25. 2023) – The ALS Association commends the FDA for approving tofersen under the agency’s accelerated approval pathway for the treatment of people living with ALS connected to mutations in the SOD1 gene.
A “Game-Changer” – Groundbreaking Discovery Paves Way for ALS …
WEBMay 29, 2024 · In a groundbreaking Canadian discovery powered by philanthropy, a team of Western University researchers led by Dr. Michael Strong has uncovered a potential path toward a cure for amyotrophic lateral sclerosis (ALS).
Amyotrophic Lateral Sclerosis News -- ScienceDaily
WEBMar 13, 2024 · Latest research news on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, including experimental treatments.
Scientists may have discovered a potential cure for ALS - The Toronto Star
WEBMay 17, 2024 · A team of researchers at Western University have made a major breakthrough that could pave the way to a cure for amyotrophic lateral sclerosis (ALS) — a devastating nervous system disease that...
FDA final approval decision on NurOwn for ALS due by year’s end
WEBJun 8, 2023 · A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8.
Phase 1 clinical trial of experimental ALS therapy ... - ALS News …
WEBAug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
News - The ALS Association
WEBStay up to date with the latest ALS news, with stories centered around research, care services, and advocacy.
ALS Breakthrough: New DNA Treatment Could Delay Paralysis
WEBMay 12, 2023 · “Without stathmin-2, motor neurons disconnect from muscle, driving paralysis that is characteristic of ALS. What we have now found is that we can mimic TDP-43 function with a designer DNA drug, thereby restoring correct stathmin-2 RNA and protein level in the mammalian nervous system.”